series-a
Stage
1
Investors
About
Rapafusyn develops novel therapeutics using proprietary RapaGlues, a class of non-degrading molecular glues that induce protein-protein interactions to target previously undruggable intracellular proteins, with applications in oncology, immunology, and acute kidney injury.
Explore Rapafusyn's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.